A multidisciplinary team of researchers from the USC Dana and David Dornsife College of Letters, Arts and Sciences and the USC School of Pharmacy demonstrated a way to generate potential new Human Immunodeficiency Virus (HIV) drugs by inhibiting a crucial enzyme in the HIV replication cycle. New HIV medicines are critically needed because HIV mutates quickly into drug-resistant strains, rendering older medicines ineffective. The research team, led by Kyung Jung, PhD, associate professor of chemistry, USC Dana and David Dornsife College of Letters, Arts and Sciences, received pilot funds from the SC CTSI to investigate new HIV integrase inhibitors. They recently filed for patent approval and are now examining new clinical applications for their discovery.

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.